Ozics Holdings, Ltd appoints Jeff F. Doerzbacher as Vice President, Clinical, Regulatory and Quality

HAMILTON, Bermuda - Oct. 12, 2015 - PRLog -- Ozics Holdings, Ltd. (www.ozicsholdings.com), a rapidly growing medical device company with high-strength, injectable, biocomposite technology intended to be used to improve the treatment of fragility fractures, is

pleased to announce the appointment of Jeff F. Doerzbacher as Vice President, Clinical, Regulatory and Quality. Mr Doerzbacher's first task will be preparing the data and documentation for the 510(k) submission to gain market clearance for the Ozics' lead product CompO6 in the United States.

Mr Doerzbacher has spent the past 27 years working in leading medical device companies including Sulzer Orthopedics, Smith & Nephew and Abbott Spine in research, regulatory, and clinical trial functions. His job specific skills include clinical trial protocol development and execution, and regulatory filing experience in the medical device, pharmaceutical and biologics industries, as well as applied statistical knowledge, technical writing and editing, data management and programming,. His experience working cooperatively and effectively communicating with regulatory authorities will be of importance in furthering Ozics’ global regulatory strategy.

Dr Auvo Kaikkonen, President of Ozics, said, “I am very pleased to welcome Jeff to the team at Ozics. Following our successful listings in Bermuda and Frankfurt, we are looking to continue to build momentum in our core business to improve the treatment of fragility fractures. Jeff will play a key role in ensuring our products meet the highest manufacturing standards, gaining regulatory approvals and in providing clinical data necessary to support our marketing efforts to enable us to deliver the growth that we anticipate. We are confident that, with his experience, Jeff will make a valuable contribution to our growing business.”

About Ozics:

Ozics was founded to develop and commercialize novel, high-strength, injectable, biocomposites to improve the treatment of fragility fractures. Through collaborative partnerships, technology licensing, and internal research and development efforts, Ozics delivers innovative products that are less invasive, improve patient outcomes, and lower the cost of caring for patients with fragility fractures.